TABLE OF CONTENTS
Volume 86, Issue 5 (November 2009)
Editorial |
News & Views |
Perspectives |
State of the Art |
Research |
Discovery & Development |
Regulation & Use
In This Issue
In This Issue
In This Issue
Clin Pharmacol Ther 86: 451; doi:10.1038/clpt.2009.202
See also: State of the Art by Goodsaid et al. See also: Reports by Fosser et al. See also: Reports by Chiang & ButteSee also: Articles by You et al. See also: Practice by SuslaEditorial
Editorial
Nephropharmacology: Drugs and the Kidney
A J Atkinson Jr and S-M Huang
Clin Pharmacol Ther 86: 453-456; doi:10.1038/clpt.2009.191
News & Views
Highlights
Highlights
Clin Pharmacol Ther 86: 458-459; doi:10.1038/clpt.2009.203
ASCPT News
ASCPT News
Clin Pharmacol Ther 86: 460-461; doi:10.1038/clpt.2009.196
Books
Clinical Physiology and Pharmacology: The Essentials
Reviewed by M J Avram
Clin Pharmacol Ther 86: 462-463; doi:10.1038/clpt.2009.189
Perspectives
Point/Counterpoint
Use of the MDRD Study Equation to Estimate Kidney Function for Drug Dosing
L A Stevens and A S Levey
Clin Pharmacol Ther 86: 465-467; doi:10.1038/clpt.2009.124
See also: Point/Counterpoint by Spruill et al.Continuing the Use of the Cockcroft–Gault Equation for Drug Dosing in Patients With Impaired Renal Function
W J Spruill, W E Wade and H H Cobb III
Clin Pharmacol Ther 86: 468-470; doi:10.1038/clpt.2009.187
See also: Point/Counterpoint by Stevens & LeveyCommentaries
How a US Regulator Can Encourage New Science
D C Throckmorton
Clin Pharmacol Ther 86: 471-472; doi:10.1038/clpt.2009.188
See also: State of the Art by Goodsaid et al.How Will GINA Influence Participation in Pharmacogenomics Research and Clinical Testing?
L G Dressler and S F Terry
Clin Pharmacol Ther 86: 472-475; doi:10.1038/clpt.2009.146
When to Conduct a Renal Impairment Study During Drug Development: US Food and Drug Administration Perspective
S-M Huang, R Temple, S Xiao, L Zhang and L J Lesko
Clin Pharmacol Ther 86: 475-479; doi:10.1038/clpt.2009.190
See also: Point/Counterpoint by Stevens & LeveySee also: Point/Counterpoint by Spruill et al.Challenges in Developing Evidence-Based Drug Dosing Guidelines for Adults and Children Receiving Renal Replacement Therapy
B A Mueller and W E Smoyer
Clin Pharmacol Ther 86: 479-482; doi:10.1038/clpt.2009.150
State of the Art
State of the Art
Drug Dosing in Patients With Impaired Renal Function
D C Brater
Clin Pharmacol Ther 86: 483-489; advance online publication, July 22, 2009; doi:10.1038/clpt.2009.135
Novel Biomarkers of Acute Kidney Toxicity
F M Goodsaid, M Blank, F Dieterle, P Harlow, E Hausner, F Sistare, A Thompson and J Vonderscher
Clin Pharmacol Ther 86: 490-496; advance online publication, August 26, 2009; doi:10.1038/clpt.2009.149
See also: Commentaries by ThrockmortonResearch
Reports
Population Analyses of Atorvastatin Clearance in Patients Living in the Community and in Nursing Homes
J B Schwartz and D Verotta
Clin Pharmacol Ther 86: 497-502; advance online publication, July 1, 2009; doi:10.1038/clpt.2009.100
Comparison of Manual and Automated Measurements of the QT Interval in Healthy Volunteers: An Analysis of Five Thorough QT Studies
C Fosser, G Duczynski, M Agin, P Wicker and B Darpo
Clin Pharmacol Ther 86: 503-506; advance online publication, April 1, 2009; doi:10.1038/clpt.2009.34
Systematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses
A P Chiang and A J Butte
Clin Pharmacol Ther 86: 507-510; advance online publication, July 1, 2009; doi:10.1038/clpt.2009.103
Articles
Association of CYP2B6, CYP3A5, and CYP2C19 Genetic Polymorphisms With Sibutramine Pharmacokinetics in Healthy Korean Subjects
K A Kim, W K Song and J Y Park
Clin Pharmacol Ther 86: 511-518; advance online publication, August 19, 2009; doi:10.1038/clpt.2009.145
Pharmacokinetic Study of Pegylated Liposomal CKD-602 (S-CKD602) in Patients With Advanced Malignancies
W C Zamboni, S Strychor, L Maruca, S Ramalingam, B A Zamboni, H Wu, D M Friedland, R P Edwards, R G Stoller, C P Belani and R K Ramanathan
Clin Pharmacol Ther 86: 519-526; advance online publication, August 12, 2009; doi:10.1038/clpt.2009.141
Effects of Selective Serotonin Reuptake Inhibitor Therapy on Endothelial Function and Inflammatory Markers in Patients With Coronary Heart Disease
C Pizzi, S Mancini, L Angeloni, F Fontana, L Manzoli and G M Costa
Clin Pharmacol Ther 86: 527-532; advance online publication, July 29, 2009; doi:10.1038/clpt.2009.121
Hydrochlorothiazide and Atenolol Combination Antihypertensive Therapy: Effects of Drug Initiation Order
J A Johnson, Y Gong, K R Bailey, R M Cooper-DeHoff, A B Chapman, S T Turner, G L Schwartz, K Campbell, S Schmidt, A L Beitelshees, E Boerwinkle and J G Gums
Clin Pharmacol Ther 86: 533-539; advance online publication, July 1, 2009; doi:10.1038/clpt.2009.101
Potential Clinical and Economic Outcomes of CYP2C9 and VKORC1 Genotype-Guided Dosing in Patients Starting Warfarin Therapy
J H S You, K K N Tsui, R S M Wong and G Cheng
Clin Pharmacol Ther 86: 540-547; advance online publication, July 1, 2009; doi:10.1038/clpt.2009.104
Discovery & Development
Translational Medicine
Pharmacokinetic Studies in Hemodialysis Patients
A J Atkinson Jr and J G Umans
Clin Pharmacol Ther 86: 548-552; advance online publication, August 12, 2009; doi:10.1038/clpt.2009.147
The Influence of Chronic Renal Failure on Drug Metabolism and Transport
A W Dreisbach
Clin Pharmacol Ther 86: 553-556; advance online publication, September 23, 2009; doi:10.1038/clpt.2009.163
Development
Drug Development Perspective on Pharmacokinetic Studies of New Drugs in Patients With Renal Impairment
R L Lalonde and J A Wagner
Clin Pharmacol Ther 86: 557-561; advance online publication, September 23, 2009; doi:10.1038/clpt.2009.182
Regulation & Use
Practice
The Impact of Continuous Renal Replacement Therapy on Drug Therapy
G M Susla
Clin Pharmacol Ther 86: 562-565; advance online publication, September 2, 2009; doi:10.1038/clpt.2009.152
